BioSpace News Archive

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it held its ordinary annual and extraordinary general meeting of shareholders on June 24, 2020.

joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is pleased to announce a new countrywide distributor in Taiwan, Hi-Clearance Inc.

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces positive clinical and translational data from Cohort B, stage 1 of in the phase II trial (BGBC008).

In an endeavor to show support and provide extra precautions during the COVID-19 pandemic, Gibson Diagnostic Labs, a leading clinical diagnostic laboratory, has donated personal protective equipment and educational resources to its partners as well as to homeless shelters, first responders and food banks to help them maintain a safe workplace environment.

PruittHealth announces that, in addition to the current COVID-19 data published on its Emergency Preparedness webpage, it has restructured its public report to align with the Centers for Disease Control and Prevention (CDC) reporting guidelines.

Company Appoints President for INOVIO Asia; Adds Senior Vice President of COVID-19 Vaccine Clinical Development

SLS-007 is Seelos’ Second Gene Therapy Program Targeting Alpha-Synuclein Top-line Data Expected Late 2020/Early 2021

Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets Agreement includes $5 million upfront payment and development and commercial milestones up to $172 million

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that Dr. Cheng Liu, President and Chief Executive Officer, is scheduled to participate at Oppenheimer’s Private Life Sciences Company Call Series on Monday, June 29, 2020. Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS ® T cell) that has b

Company executes on corporate communication strategy and advances drug branding initiatives Lead drug candidate for NSCLC now referred to as quaratusugene ozeplasmid or GPX-001 Company rebrands use of Oncoprex™ name for Nanoparticle Delivery Platform AUSTIN, Texas--( BUSINESS WIRE )-- Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies fo